Targeting self-renewal pathways in cancer stem cells: clinical implications for cancer therapy

A Borah1, S Raveendran1, A Rochani1

  • 1Bio Nano Electronics Research Center, Graduate School of Interdisciplinary New Science, Toyo University, Kawagoe, Saitama, Japan.

Oncogenesis
|December 1, 2015
PubMed

Insights

Cancer stem cells (CSCs) drive tumor growth and recurrence due to deregulated self-renewal pathways (SRPs). Targeting these SRPs with nanoformulations offers a promising strategy to improve cancer therapy by enhancing drug delivery and reducing side effects.

Area of Science:

  • Oncology
  • Cancer Biology
  • Nanotechnology

Background:

  • Cancer stem cells (CSCs) are a rare subpopulation driving tumorigenesis and metastasis.
  • CSCs possess deregulated self-renewal pathways (SRPs), conferring resistance to conventional chemotherapy and leading to tumor recurrence.
  • Current cancer treatments struggle to differentiate and target CSCs effectively due to a lack of specific biomarkers.

Purpose of the Study:

  • To investigate the complex functional biology of CSCs, focusing on signaling pathways.
  • To explore novel therapeutic strategies targeting SRPs in CSCs for improved cancer treatment.
  • To evaluate the potential of nanoformulations in selectively targeting CSC-specific pathways.

Main Methods:

  • Review of existing cancer research on CSCs and their self-renewal mechanisms.
  • Analysis of signaling pathways implicated in CSC survival and drug resistance, including Hedgehog, Wnt, Notch, and B-cell-specific moloney murine leukemia virus integration site 1.
  • Exploration of nanoformulation strategies for targeted delivery of therapeutic agents to CSCs.

Main Results:

  • Deregulated SRPs in CSCs are critical for their survival, tumorigenesis, and resistance to chemotherapy.
  • Direct targeting of SRPs with small molecules presents challenges including off-target effects, poor bioavailability, and severe side effects.
  • Nanoformulations show potential for selective targeting of SRPs in CSCs, sparing normal stem cells.

Conclusions:

  • Targeting deregulated SRPs in CSCs is a promising strategy to overcome therapeutic resistance and prevent tumor recurrence.
  • Nanoformulations offer an advantageous approach to deliver therapeutic agents selectively to CSCs, mitigating the limitations of conventional methods.
  • A comprehensive understanding of CSC molecular pathways combined with holistic nanosystems could revolutionize future cancer therapy.

Related Concept Videos

Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

2.3K
Renewal of Skin Epidermal Stem Cells01:12

Renewal of Skin Epidermal Stem Cells

The skin is divided into epidermis, dermis, and hypodermis, the skin's outermost, middle, and inner layers. The human epidermal layer regularly undergoes renewal, where old, dead cells are replaced by new cells. Epidermal stem cells or EpiSCs divide and differentiate to restore the lost cells. For the renewal process, some EpiSCs continuously self-renew. In contrast, few others differentiate into transit-amplifying cells, which later form prickle or spinous cells, followed by granular...
3.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.4K